 Summary

This study reviews medical disease and its implications. The authors have highlighted the effect

of Topical Ivermectin and IotaCarrageenan against covid-19. In this paper, they discussed about

the pandemic and then discussed in detail the key safety items against covid-19. In this paper

they followed economic principles and applications in a proper way e.g. while sampling and

calculating results, they take care of each and every participant specific percentage who are

effected by disease and who are not effected by disease, then at the end they did an overall

comparative study in order to understand things in more better way.

 Discussion of the disease or conditions

One of the most important reason for spreading the disease rapidly is human interaction between

each other in a controlled environment. During the research, it is observed that health workers

who (did not follow the proper standard operating procedures and did not use the PPE (personal

protective equipment) in normal conditions, chances of getting positive PCR report for Covid-19

is higher (Cook, 2020). According to my analysis, the article also explained the economic

principles and applications clearly and accurately, they did regression analysis in this research

article, from this regression analysis credibility of this article has increased enough as it is

mentioned p value < 0.0001, which is showing that article’ results are significant (Chahla et al.,

2021).

1
 Results and Discussions

Blue: Nurses; Orange: Anesthetiologist; gray: Lab. Personnel; ocre: ICU

(Héctor et al., 2020)

As nurses have more interaction with patients, they have to deal all kind of patients so chances

of positive report and being effected by covid-19 is more than any other professionals doing

work in the hospitals and in laborites (Kalfas et al., 2020). If we talk about the overall infection

rate in health workers, this is higher than any profession, the main reason behind is the

interaction of health workers with each different type of health patient disease. It is almost

twenty percent which is huge in numbering ratio. That’s why it is suggested that PPE is one of

the key element and protection tool that safe the human being especially give protection against

the dangerous disease in the form of covid-19 (Jans & Wagstaff, 2020; Mahmood et al., 2020).

And the same case with patients who received IVERCAR and standard PPEs, none of them test

positive for covid-19 (Hirsch and Carvallo, 2020).

2
We can see and observe that most of the participants have done with IVERCAR and due to

adoption of that powerful protection tool against covid-19, most of the participant personnel are

not affected by this disease and their covid-19 test reports are negative as per expectation (Darzi

et al., 2021). Around ninety percent personnel have received IVERCAR and just ten people are

with PPEs (Héctor et al., 2020). However, the real results are surprising and exploring the reality

of the situation about the covid-19 disease and protection from that disease.

3
Participant personnel who are following PPEs, most of them are affected by covid-19 and their

test report is positive for covid-19 test (Ali et al., 2020). But on the other hand, participant

personnel with received IVERCAR who are around nighty percent of whole testing participants,

none of them are affected by this disease (Abreu, 2020).

All the participant personnel with received IVERCAR tested negative for the covid-19. Disease.

so all the patients must be follow up with IVERCAR as soon as possible in order to be safe side

and this thing will also keep the life of nurses and paramedical staff save and protective (Kory et

al., 2021).

From all above results and

testing results, it is found that

IVERCAR is one of the most

protective tool to protect from

4
covid-19, only PPEs are not enough (Machanick, 2021). Any individual PPEs, should keep in

mind that, by only taking PPEs is not surety about full protection from the covid-19, in order to

be fully protected from covid-19 dangerous pandemic, any individual must be followed up by

IVERCAR and should follow up the proper standard operating procedures (Héctor et al., 2020;

Kory et al., 2021).

From all mentioned things in article we can conclude that patients and personnel’s who have

received IVERCAR, very less or zero chances of effecting by the covid-19 (Bartoszko et al.,

2021). At the end we also conclude that by using IVERCAR in oral solution and carrageenan in

the spray form, we can provide most effective and safe ways to protect the personnel patients and

front line medical worker staff from the most dangerous pandemic in the form of covid-19

(Bellera et al., 2021). In future there is more space of research in this research scope, in future

research can be done in order to identify more beneficial and effective protective tools against

conid-19 pandemic (Cruz, De Castro and Renz, 2020).

 Reference

5
1. Abreu, J. L. (2020). IVERMECTIN FOR THE PREVENTION OF COVID-19 So...

WHO is telling the Truth? Revista Daena (International Journal of Good Conscience),

15(2).

2. Ali, S., Noreen, S., Farooq, I., Bugshan, A., & Vohra, F. (2020). Risk assessment of

healthcare workers at the frontline against COVID-19. Pakistan journal of medical

sciences, 36(COVID19-S4), S99.

3. Bartoszko, J. J., Siemieniuk, R. A., Kum, E., Qasim, A., Zeraatkar, D., Ge, L., Han, M.

A., Sadeghirad, B., Agarwal, A., & Agoritsas, T. (2021). Prophylaxis against covid-19:

living systematic review and network meta-analysis. bmj, 373.

4. Bellera, C. L., Llanos, M., Gantner, M. E., Rodriguez, S., Gavernet, L., Comini, M., &

Talevi, A. (2021). Can drug repurposing strategies be the solution to the COVID-19

crisis? Expert Opinion on Drug Discovery, 16(6), 605-612.

5. Chahla, R. E. et al. (2021) ‘A randomized trial-intensive treatment based in Ivermectin

and Iota-Carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents’,

medRxiv.

6. Cook, T. (2020). Personal protective equipment during the coronavirus disease (COVID)

2019 pandemic–a narrative review. Anaesthesia, 75(7), 920-927.

7. Cruz, M. G. D., De Castro, L. R. O. and Renz, D. L. (no date) ‘Should ivermectin be used

as COVID-19 prophylaxis for the general population?’

8. Hirsch, R. R. and Carvallo, H. E. (2020) ‘Ivermectin as Prophylaxis Against COVID-19

Retrospective Cases Evaluation’, Microbiol Infect Dis, 4(4), pp. 1–8.

6
9. Darzi, A., Ghadimi, M., Lamontagne, F., & Loeb, M. (2021). Prophylaxis against covid-

19: living systematic review and network meta-analysis.

10. Héctor, C., Roberto, H., Psaltis, A., & Veronica, C. (2020). Study of the efficacy and

safety of topical ivermectin+ iota-carrageenan in the prophylaxis against COVID-19 in

health personnel. J biomed res clin investig, 2(1).

11. Jans, D. A., & Wagstaff, K. M. (2020). Ivermectin as a broad-spectrum host-directed

antiviral: the real deal? Cells, 9(9), 2100.

12. Kalfas, S., Visvanathan, K., Chan, K., & Drago, J. (2020). The therapeutic potential of

ivermectin for COVID-19: A review of mechanisms and evidence. medRxiv.

13. Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021). Review of the

Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and

Treatment of COVID-19. American Journal of Therapeutics, 28(3), e299.

14. Machanick, P. (2021). IVERMECTIN: COVID-19 MIRACLE CURE OR CRUEL

HOAX?

15. Mahmood, S. U., Crimbly, F., Khan, S., Choudry, E., & Mehwish, S. (2020). Strategies

for rational use of personal protective equipment (PPE) among healthcare providers

during the COVID-19 crisis. Cureus, 12(5).